Statin drugs do not affect serum complement activation in vitro

Scandinavian Journal of Immunology

Volumn 60, Issue 1, 2004, Pages 178-183

  Lappegard K T ^a,b   Hvassing, T ^a   Mollnes, T E ^a,c  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ATORVASTATIN; COMPLEMENT; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LECTIN; PRAVASTATIN;

ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; DRUG EFFECT; HUMAN; IMMUNOGLOBULIN AGGREGATE; INCUBATION TIME; PRIORITY JOURNAL;

COBRA VENOMS; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; HEPTANOIC ACIDS; HUMANS; IMMUNOGLOBULINS; PRAVASTATIN; PYRROLES;

EID: 3242715168     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01439.x     Document Type: Article

References (55)

1. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
2. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
5. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation 2002;106:2041-2.
6. Mason JC. Statins and their role in vascular protection. Clin Sci (Lond) 2003;105:251-66.
7. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
8. de Lemos JA, Morrow DA, Sabatine MS et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107:690-5.
9. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999;353:118-9.
10. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol 1999;36:949-55.
11. Muscari A, Massarelli G, Bastagli L et al. Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol 1998;53:345-54.
12. Muscari A, Bozzoli C, Puddu GM et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995;98:357-64.
13. Halkes CJ, van Dijk H, de Jaegere PP et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 2001;21:1526-30.
14. Muscari A, Bastagi L, Poggiopollini G et al. Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. Cardiovasc Drugs Ther 2001;15:453-8.
15. Di Garbo V, Cordova R, Awelone G. Increased thrombin generation and complement activation in patients with type IIa hyperlipoproteinemia: effects of simvastatin treatment. Curr Ther Res Clin Exp 1997;58:706-23.
16. Fure H, Nielsen EW, Hack CE, Mollnes TE. A neoepitope-based enzyme immunoassay for quantification of C1- inhibitor in complex with C1r and C1s. Scand J Immunol 1997;46:553-7.
17. Wolbink GJ, Bollen J, Baars JW et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993;163:67-76.
18. Mollnes TE, Brekke OL, Fung M et al. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002;100:1869-77.
19. Mollnes TE. Analysis of in vivo complement activation. In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, eds. Weir's Handbook of Experimental Immunology. Boston, MA: Blackwell Science 1997.
20. Jukema JW, Bruschke AV, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) Circulation 1995;91:2528-40.
21. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
22. Egashira K, Hirooka Y, Kai H et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-24.
23. Treasure CB, Klein JL, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
24. Vita JA, Yeung AC, Winniford M et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000;102:846-51.
25. Mitropoulos KA, Armitage JM, Collins R et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J 1997;18:235-41.
26. Bevilacqua M, Bettica P, Milani M et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997;79:84-7.
27. Isaacsohn JL, Setaro JF, Nicholas C et al. Effects of lovastatin therapy on plasminogen acrivator inhibitor-1 antigen levels. Am J Cardiol 1994;74:735-7.
28. Wada H, Mori Y, Kaneko T et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992;14:829-34.
29. Davidson M, McKenney J, Stein E et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997;79:1475-81.
30. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:1527-31.
31. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996;122:225-33.
32. Bo M, Bonino F, Neirotti M et al. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991;42:106-13.
33. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993;70:241-3.
34. 2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin. Arterioscler Thromb Vasc Biol 1995;15:759-64.
35. Beigel Y, Fuchs J, Snir M, Green P, Lurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 1991;31:512-7.
36. Davi G, Averna M, Novo S et al. Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients. Atherosclerosis 1989;79:79-83.
37. Mayer J, Eller T, Brauer P et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992;64:196-201.
38. Notarbartolo A, Davi G, Averna M et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-51.
39. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
40. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9.
41. Lau WC, Waskell LA, Watkins PB et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7.
42. Serebruany VL, Steinhubl SR, Hennekens CH. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation 2003;107:1568-9.
43. Saw J, Steinhubl SR, Berger PB et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4.
44. Wienbergen H, Gitt AK, Schiele R et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003;92:285-8.
45. Mollnes TE, Song WC, Lambris JD. Complement in inflammatory tissue damage and disease. Trends Immunol 2002;23:61-4.
46. Yoshimura A, Inui K, Nemoto T et al. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 1999;9:2027-39.
47. Neale TJ, Ojha PP, Exner M et al. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest 1994;94:1577-84.
48. Mason JC, Ahmed Z, Mankoff R et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002;91:696-703.
49. Viedt C, Shen W, Fei J et al. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res Cardiol 2003;98:353-61.
50. Fischetti F, Carretta R, Borotto G et al. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 2004;135:186-93.
51. Verseyden C, Meijssen S, van Dijk H, Jansen H, Castro CM. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J Lipid Res 2003;44:2100-8.
52. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
53. Nijmeijer R, Lagrand WK, Lubbers YT et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 2003;163:269-75.
54. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5.
55. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-8.